Biotechnology · La Jolla, California, United States
$1.39
-0.07% (-$0.00)2026-07-09
Smart-Money SignalNeutral · 51/100— Insider open-market flow is flat over 90 days
Revenue$187.0K
Net Income-$2.6M
EPS$-0.05
Market Cap$68.4M
Price Performance
Historical data including institutional events
Company Profile
Y
Yuichi Iwaki
CEO & Executive Director
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
- Founded
- 2000
- Employees
- 6
- Headquarters
- La Jolla, California, United States
- Website
- medicinova.com
Peer ComparisonRevenue ($B)
▾Loading company sections...